The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
Cureus · 21.06.2023
DOI: 10.7759/cureus.40719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cureus, erschienen am 21.06.2023. Verfasst von Naushad Abid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, King Faisal University College of Medicine, Al-Ahsa, SAU. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
There is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled trials (RCTs) have evaluated these two agents' clinical efficacy and safety in different manifestations of SLE. This study aims to review the randomized control trials involving these two agents systematically and to explain if any disparity is noticed in the primary and secondary outcomes between these two agents. This study is done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After applying the inclusion criteria and quality assessment by independent reviewers and co-authors, relevant papers were identified, and data were extracted. The results have shown that RCTs involving Belimumab achieved primary endpoints; however, targeted endpoints were not achieved in studies involving Rituximab. It is concluded that despite the conflicting results obtained in clinical trials, both are effective in systemic lupus, as indicated in real-world clinical experience. However, better-designed multicenter studies evaluating these B-cell-targeting drugs are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, King Faisal University College of Medicine, Al-Ahsa, SAU.
- Internal Medicine / Rheumatology, King Faisal University, Al-Ahsa, SAU.
- Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
- Medicine and Surgery, Dow International Medical College, Dow University of Health Sciences, Karachi, PAK.
- Internal Medicine, Bidar Institute of Medical Sciences, Bidar, IND.
- Medicine and Surgery, Universidad Latina de Panama, Panama City, PAN.
Zitieren
APA
Abid, N., Manaye, S., Naushad, H., Cheran, K., Murthy, C., Bornemann, E. A., Kamma, H. K., Alabbas, M., & Elashahab, M. (2023). The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review. Cureus. https://doi.org/10.7759/cureus.40719
Vancouver
Abid N, Manaye S, Naushad H, Cheran K, Murthy C, Bornemann EA, et al. The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review. Cureus. 2023. doi:10.7759/cureus.40719
BibTeX
@article{Abid2023,
author = {Abid, Naushad and Manaye, Sara and Naushad, Hamzah and Cheran, Kaaviya and Murthy, Chinmayee and Bornemann, Elisa A and Kamma, Hari Krishna and Alabbas, Mohammad and Elashahab, Mohammed},
title = {The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review},
journal = {Cureus},
year = {2023},
doi = {10.7759/cureus.40719}
}
EUVIMED